Brokerage firm Roth Capital Upgrades its rating on EXACT Sciences Corporation(EXAS). The shares have been rated Buy. Previously, the analysts had a Neutral rating on the shares. The rating by the stock financial advisor at Roth Capital was issued on Feb 22, 2017 in a research report to their Investors and Clients.
EXACT Sciences Corporation (EXAS) made into the market gainers list on Wednesdays trading session with the shares advancing 1.25% or 0.28 points. Due to strong positive momentum, the stock ended at $22.69, which is also near the day’s high of $23.4. The stock began the session at $22.95 and the volume stood at 56,54,133 shares. The 52-week high of the shares is $23.68 and the 52 week low is $4.67. The company has a current market capitalization of $2,460 M and it has 10,84,10,279 shares in outstanding.
EXACT Sciences Corporation(EXAS) last announced its earnings results on Oct 26, 2016 for Fiscal Year 2016 and Q3.Company reported revenue of $28.11M. Analysts had an estimated revenue of $25.24M. Earnings per share were $-0.36. The reported EPS was above estimates by $0.07 or 16.28%. Analysts had estimated an EPS of $-0.43.
Several Insider Transactions has been reported to the SEC. On Jan 5, 2017, D Scott Coward (SVP and General Counsel) sold 1,535 shares at $13.61 per share price.Also, On Dec 14, 2016, David Thompson (director) purchased 10,000 shares at $13.84 per share price.On Nov 15, 2016, Graham Peter Lidgard (Chief Science Officer) sold 311,112 shares at $17.52 per share price, according to the Form-4 filing with the securities and exchange commission.
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company has developed a non?invasive screening test called Cologuard for colorectal cancer. Its Cologuard test is a non?invasive stool?based deoxyribonucleic acid (DNA) (sDNA) screening test designed to detect DNA markers. In addition to DNA markers its test includes a protein marker to detect blood in the stool utilizing an antibody?based fecal immunochemical test (FIT). The Company’s Cologuard test is designed to detect pre?cancerous lesions or polyps and each of the four stages of colorectal cancer. By detecting pre?cancers and cancers early with its test affected patients can be referred to colonoscopy during which the polyps or lesions can be removed. The company’s test also detects blood in stool utilizing an antibody based FIT test.